A paper review on combining PRF and CaHA

This article discusses the source author’s earlier literature, cases and experiences. Research populations and limitations matter; individual diagnosis and treatment require clinical assessment.

The source discusses whether platelet-rich fibrin, or PRF, changes the timing of observed outcomes with CaHA. PRF differs from PRP in preparation and structure. Being derived from the patient’s blood does not eliminate infection or procedural risks.

The source describes a Colombian study of 100 patients, comparing CaHA with saline and lidocaine against CaHA with PRF. Exact methods, allocation, outcome definitions and follow-up need checking before interpreting the comparison.

The source reports perceived changes at one to two weeks in the PRF group versus after about four weeks in the other group, 70% reporting no initial effect loss versus 84% reporting loss, and 74% versus 10% rating themselves “very improved” at day 15. These figures are not guaranteed patient outcomes. No reported adverse event is not proof of no risk.

Mechanisms and observations

Growth factors and the fibrin matrix are proposed to influence tissue response. They do not establish a formula of faster onset plus longer duration. Photographs show individual courses.

Reference cited: Julián Hernández et al. Platelet-rich fibrin and calcium hydroxyapatite (CaHA): The perfect combination to accelerate, potentiate, and extend skin rejuvenation. Aesthetic Medicine. 2024;10(1):e2024007.

The source’s numbers and time points require original-paper comparison. This article does not confirm that the combination is currently offered by the clinic.

Materials linked by the source

• Source material 1